OTLK Financials Outlook Therapeutics, Inc.
11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $1M | -$62M | 4.0% | -4744.3% | 193.9% | -335.9% | — | — | $8M |
| 2024 | — | -$75M | — | — | 103.1% | -261.5% | — | — | $15M |
| 2023 | — | -$59M | — | — | 408.5% | -182.6% | — | — | $23M |
| 2022 | — | -$66M | — | — | -756.0% | -231.5% | — | — | $17M |
| 2021 | — | -$53M | — | — | -1153.9% | -233.1% | — | — | $14M |
| 2020 | — | -$35M | — | — | -1246.8% | -178.6% | — | — | $13M |
| 2019 | — | -$35M | — | — | 214.0% | -201.5% | -$33M | $1.1B | $8M |
| 2018 | — | -$30M | — | — | 117.8% | -135.0% | -$36M | $164967 | $2M |
| 2017 | — | -$39M | — | — | 115.4% | -187.4% | -$16M | $203710 | $3M |
| 2016 | — | -$53M | — | — | 1030.4% | -209.8% | — | $3M | $2M |
| 2015 | — | -$47M | — | — | 87.4% | -135.4% | — | $3M | $9M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$20M | — | — | 195.5% | -77.6% | — | — | $11M |
| Mar '26 | — | -$4M | — | — | 15.4% | -20.3% | — | — | $8M |
| Dec '25 | — | -$23M | — | — | 59.8% | -126.4% | — | — | $9M |
| Sep '25 | -$91787 | -$13M | 1098.5% | 18863.9% | 41.3% | -71.5% | — | — | $8M |
| Jun '25 | $2M | -$20M | 70.8% | -1046.2% | 54.2% | -90.0% | — | — | $9M |
| Mar '25 | — | -$46M | — | — | 142.8% | -243.0% | — | — | $8M |
| Dec '24 | — | $17M | — | — | -34.6% | 102.2% | — | — | $6M |
| Sep '24 | — | $6M | — | — | -7.8% | 19.7% | — | — | $15M |
| Jun '24 | — | $44M | — | — | -53.1% | 94.3% | — | — | $32M |
| Mar '24 | — | -$114M | — | — | 85.1% | -193.6% | — | — | $47M |
| Dec '23 | — | -$11M | — | — | 45.9% | -51.5% | — | — | $10M |
| Sep '23 | — | -$13M | — | — | 90.0% | -40.2% | — | — | $23M |
| Jun '23 | — | -$21M | — | — | 375.7% | -46.5% | — | — | $34M |
| Mar '23 | — | -$7M | — | — | -63.4% | -12.3% | — | — | $44M |
| Dec '22 | — | -$19M | — | — | -118.4% | -29.8% | — | — | $52M |
| Sep '22 | — | -$14M | — | — | -164.2% | -50.3% | — | — | $17M |
| Jun '22 | — | -$18M | — | — | -87.3% | -45.5% | — | — | $26M |
| Mar '22 | — | -$20M | — | — | -54.8% | -29.1% | — | — | $58M |
| Dec '21 | — | -$14M | — | — | -29.6% | -18.4% | — | — | $70M |
| Sep '21 | — | -$13M | — | — | -290.9% | -58.8% | — | — | $14M |
Valuation over time
How the market has priced OTLK against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 181.7× (Sep '25) to 112.2× (Sep '26).
Frequently asked questions
Is OTLK growing its revenue and profit?
See the revenue and net-income charts above for Outlook Therapeutics, Inc.'s multi-year trend.
How much debt does OTLK have?
As of FY2025, Outlook Therapeutics, Inc. reported — of total debt against $8M of cash.
What is OTLK's profit margin?
In FY2025, gross margin was 4.0%, operating margin -4744.3%, and net margin -4416.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.